Windtree Therapeutics Inc (WINT)

[Monksdream]

WINT new 52=week low

[Roadtojourney]

Yup they pr only to dilute there share pos?? Imo

[Mr. Zen]

Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced the trial design of its SEISMiC Phase 2b has been published by the European Society of Cardiology Heart Failure. The article is entitled, “Safety and efficacy of up to 60 hours of intravenous istaroxime in pre-cardiogenic shock patients: Design of the SEISMiC trial.” It can be found online in Wiley Online Library DIO: 10.1002/ehf2.15102. Results can be viewed at https://ir.windtreetx.com/corporate-presentation. The Heart Failure Society of America also shared the results.

[tw0122]

$1.26 + 36%

[tw0122]

Pump it

[Monksdream]

WINT anew 52 week low

[Monksdream]

WINT under $2

[Mr. Zen]

Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock

[Monksdream]

WINT new 52 week low

[Awl416]

On September 25, 2024, Windtree Therapeutics, Inc. (the “Company”) issued a press release announcing positive topline results from the Company’s Phase 2b SEISMiC Extension Study of istaroxime in treating early cardiogenic shock due to heart failure. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

[glenn1919]

WINT...................................................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783

[na na]

There's a big borrowing fee. 50 dollars in losses per 1000 dollars of shorted shares per day.

[tw0122]

FOR RESALE OF UP TO 27.7 MILLION SHARES BY THE SELLING STOCKHOLDERS - SEC FILING Source text for Eikon: Further company coverage:

Wow!!

[tw0122]

My bad 10 million shares offering announced recently this won’t go anywhere. Share selling machine short it

[tw0122]

Pop it to $5 already another 400k floater $3.85 resistance watch

[Awl416]

Don’t blink

[na na]

If you short 1000 dollars of shares you're now paying 70 dollars a day in fees,Up from 50 dollars of fees a few days ago.

[na na]

Jumped from 700 percent to 800 percent borrow fee.

[Anite]

For the upcoming trading day on Friday, 6th we expect Windtree Therapeutics Inc to open at $3.05 and during the day (based on 14 day Average True Range), to move between $3.10 and $4.75, which gives a possible trading interval (+/-54.61%) up from last closing price. If Windtree Therapeutics Inc takes out the full calculated possible swing range there will be an estimated 109.21% move between the lowest and the highest trading price during the day.

[Anite]

Last week:First, the private placement delivers needed capital to support company operations, including the active Phase 2b clinical trial for istaroxime in cardiogenic shock. Second, the transaction fully converted and eliminated senior notes, including senior secured notes we used as bridge financing over the past several months eliminating this debt from our balance sheet.” 
Windtree shares are blasting higher on heavy volume Friday with more than 9 million shares

[Anite]

Borrow rates now 1500%!!!!!

[Mr. Zen]

Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced it has successfully completed enrollment in its SEISMiC Extension Phase 2b study of istaroxime in early cardiogenic shock caused by heart failure. The study is evaluating the ability of istaroxime to improve heart function and low blood pressure in the setting of early cardiogenic shock due to heart failure. The Company is looking to extend the positive results on these parameters as observed in the Company’s first SEISMiC Phase 2 clinical study that was previously reported. In addition, the Company hopes that the study results will substantiate the encouraging observations from the Company’s Phase 2 clinical study, indicating istaroxime has a favorable renal profile and does not increase cardiac arrhythmias. The SEISMiC Extension Study is utilizing longer dosing duration and tapering the dosing to assess the potential benefits.

Istaroxime is a novel first-in-class therapy that has demonstrated the ability to improve systolic contraction and diastolic relaxation of the heart while also increasing blood pressure and maintaining or improving renal function in patients with compromised cardiac function in three positive Phase 2 trials enrolling patients with acute heart failure (AHF). Cardiogenic shock is a serious condition that can occur when AHF patients continue to deteriorate and the heart cannot pump enough blood and oxygen to the brain, kidneys, and other vital organs. Mortality rates are significant and, depending on severity, range from 7% to 40% in the U.S. There is a lack of satisfactory pharmacological intervention to reverse the condition as available therapies have unwanted side effects such as risk for arrhythmias, decreased blood pressure, and renal dysfunction that limit their usefulness and position them as “rescue medicines” for severe cases. The cardiogenic shock worldwide total market value is estimated to be $1.25 billion per year.

[na na]

RIP SHORTS! 50 dollars per 1000 dollars of share fee.

[na na]

[Awl416]

Oh cmon

[na na]

SQUEEZE!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

700 percent borrowing rate!!!


If you short 1000 dollars of stock you pay a fee of 52 dollars a day!

[willlbone]

Get up and go, got up and WINT.

[na na]

Buy the dip!!

[TIMGZ]

WHAAAAT**** LARGEST SHORT INTEREST****44%

[Monksdream]

WINT 10Q due AUGUST 20

[Awl416]

Watch out

[Awl416]

Quite the close

[Monksdream]

WINT under $9

[Zardiw]

$WINT +200% #DDAmanda Video Analysis - #1 Stock Scanner/Screener

Z

[PaladinOcean33]

WINT 4.40s

[Mr. Zen]

That is what phase three trials are all about, do not expect much for another 6 to 9 months. Then it is either break out or bust, dig into it a bit.

[Luckysevens]

“They just have to prove it” yeah thats the problem lolz

[peterus]

relax bro i will do some dd

[Mr. Zen]

no do some research here,they have a product that works they just have to prove it. Its call [phase three results, God I am so tired of these mouthy kids on this site

[peterus]

$30 YES after R/S

[Mr. Zen]

The monster run will happen, but not before phase 3 trials are released or a buyout happens, holding and looking for $30. a share plus

[everton44]

WINT, sold a ton at 8-8.10, have some left hoping for another monster run.

[Mr. Zen]

Here we go, pre-market windup.

[TheFinalCD]

DR Incredouble you trade any WINT?

[Monksdream]

Whoops, I did it, again

[tw0122]

The Company submits this request for withdrawal as it does not intend to pursue, at this time, the public offering to which the Registration Statement relates. The Registration Statement has not been declared effective by the Commission and no securities have been issued or sold under the Registration Statement. Accordingly, withdrawal of the Registration Statement is consistent with the public interest and the protection of investors, as contemplated by paragraph (a) of Rule 477.

The Company requests that, in accordance with Rule 457(p) under the Securities Act, all fees paid to the Commission in connection with the filing of the Registration Statement be credited for future use.

Pursuant to Rule 477(b), the Company understands that this request for withdrawal of the Registration Statement will be deemed granted as of the date hereof unless the Company receives notice from the Commission within 15 days of the date hereof that such request will not be granted.

If you have any questions or require any further information, please contact the Company’s counsel, Goodwin Procter LLP, by calling Justin S. Platt, Esq. at [phone].

[tw0122]

WINT 5.50s

[tw0122]

WINT 4.40s

[Monksdream]

WINT new 52 week low

[Mr. Zen]

to acquire up to the aggregate number of 3,440,631 additional shares of the Company’s common stock, $0.001 par value per share,